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Minor groove alkylating agents are a relatively new class of anti-
cancer agents reported to possess high cytotoxic activity in in vitro
and in vivo preclinical models (Li et al, 1982, 1992; Hartley et al,
1988; D’Incalci et al, 1997). Their mode of action, although not
completely clarified, is likely to involve the formation of adducts,
mainly at adenine N3 in the minor groove of DNA (Hurley et al,
1984; Reynolds et al, 1985; Sun et al, 1992; D’Incalci, 1994;
Broggini et al, 1995). For all the compounds tested so far, the
interaction with DNA and the binding to the N3 of adenines has
been reported to be highly sequence-specific (Lee et al, 1993;
D’Incalci, 1994), contrasting with the relatively low sequence-
specific DNA interaction previously reported for classical major
groove alkylating agents (Hartley et al, 1986; Mattes et al, 1986).
Tallimustine, a benzoyl mustard derivative of distamycin A,
presented a particularly strong sequence-specific DNA interaction,
being able to alkylate N3 of adenines only when they are present in
the sequence 5¢-TTTTGA (Broggini et al, 1991, 1995). These data
have been confirmed in intact cells exposed to pharmacologically
relevant drug concentrations (Beccaglia et al, 1996). Furthermore,
for tallimustine derivatives closely structurally related, the cyto-
toxic activity in vitro was found to correlate with their ability to
alkylate N3 adenine in the above-mentioned sequence (Marchini
et al, 1998).
The absence of significant anti-tumour activity for the non-
alkylating minor groove binder distamycin, from which tallimus-
tine was derived, further supports the evidence that N3 alkylation
is a pre-requisite for the cytotoxic activity of these compounds.
This was also shown for new tallimustine derivatives which were
not able to alkylate DNA and also did not exert cytotoxic activity
in vitro (Marchini et al, 1998).
Tallimustine was effective against several rodent and human
tumours, but in humans it showed a very high bone marrow
toxicity (Sessa et al, 1994; D’Incalci et al, 1997; Ghielmini et al,
1997). A series of other distamycin derivatives was synthesized
and tested for anti-tumour activity and bone marrow toxicity: one
possessing a favourable therapeutic index (i.e. high anti-tumour
activity with relatively low bone marrow toxicity) was the
a-bromoacryloyl derivative of distamycin A (PNU 151807)
(D’Alessio et al, 1994; Ghielmini et al, 1997). We report here the
characterization of the interaction of this new compound with
DNA and studies on its mechanism of action.
MATERIALS AND METHODS
Cells
The human ovarian carcinoma cell line A2780 and its subline
A2780/E6 (Vikhanskaya et al, 1998), derived from parental cells
by transfection with the DNA encoding for the E6 protein of
the human papillomavirus 16 (HPV16) under the control of the
cytomegalovirus (CMV) promoter, the B16F10 murine melanoma,
the murine lymphocytic leukaemia L1210 and the human T-cell
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Summary PNU 151807 is a new synthetic a-bromoacryloyl derivative of distamycin A. In the present study we investigated the DNA
interaction and the mechanism of action of this compound in parallel with the distamycin alkylating derivative, tallimustine. PNU 151807
possesses a good cytotoxic activity in in vitro growing cancer cells, even superior to that found for tallimustine. By footprinting experiments we
found that PNU 151807 and tallimustine interact non-covalently with the same AT-rich DNA regions. However, differently from tallimustine,
PNU 151807 failed to produce any DNA alkylation as assessed by Taq stop assay and N3 or N7-adenine alkylation assay in different DNA
sequences. PNU 151807, like tallimustine, is able to induce an activation of p53, and consequently of p21 and BAX in a human ovarian
cancer cell line (A2780) expressing wild-type p53. However, disruption of p53 function by HPV16-E6 does not significantly modify the
cytotoxic activity of the compound. Flow cytometric analysis of cells treated with equitoxic concentrations of PNU 151807 and tallimustine
showed a similar induction of accumulation of cells in the G2 phase of the cell cycle but with a different time course. When tested against
recombinant proteins, only the compound PNU 151807 (and not tallimustine or distamycin A) is able to abolish the in vitro kinase activity of
CDK2–cyclin A, CDK2–cyclin E and cdc2–cyclin B complexes. The results obtained showed that PNU 151807 seems to have a mechanism
of action completely different from that of its parent compound tallimustine, possibly involving the inhibition of cyclin-dependent kinases
activity, and clearly indicate PNU 151807 as a new non-covalent minor groove binder with cytotoxic activity against cancer cells.
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Correspondence to: M Brogginileukaemia Jurkat were maintained in RPMI-1640. The human
lymphoblastic leukaemia cell line CEM was maintained in EMEM
(Bio Whittaker), the human colon adenocarcinoma LoVo and
HT29 in Ham’s F12 medium (Bio Whittaker) and the human
prostatic carcinoma DU145 in DMEM. All media were supple-
mented with 10% fetal calf serum (FCS).
In vitro drug sensitivity
In vitro drug sensitivity was determined for LoVo, HT29, DU 145,
B16F10 and A2780 cells by using the sulphorhodamine B assay.
Exponentially growing cells were seeded 24 h before treatment,
exposed to drugs for 1 h and then incubated in drug-free medium
for 72 h. In vitro drug sensitivity against CEM, Jurkat and L1210
cells was evaluated by counting surviving cells. Exponentially
growing cells were seeded and exposed to various concentrations
of drugs immediately after seeding. The incubation mixture was
kept at 37°C for 1 h, after which the cells were washed and incu-
bated for 72 h (48 h for L1210) in drug-free medium. The antipro-
liferative activity of the drugs was calculated from dose–response
curves and expressed as IC50 (dose causing 50% inhibition of cell
growth in treated cultures relative to untreated controls).
Cell cycle analysis
A2780 cells were treated with equitoxic concentrations of
tallimustine and PNU 151807 for 1 h. Monoparametric cell cycle
analysis on ethanol-fixed cells using propidium iodide was carried
out on control and treated cells at different times after drug
washout. Each cytometric DNA analysis was performed on the
FACSSort (Becton Dickinson) on 1–2 ´ 104 cells and the
percentage of cells in the different cell cycle phases was evaluated
as previously described (Broggini et al, 1991).
Sequence specificity of adenine N3 and N7 alkylation
The method has been previously described in detail (Reynolds
et al, 1985; Marchini et al, 1995). Briefly, EcoRI (NEB) digested
SV 40 viral DNA (Gibco, BRL) was g-32P-labelled at its 5¢ ends
with T4 polynucleotide kinase (NEB). A second cut with BamHI
(NEB) was performed to produce a 4492 and a 751 bp fragments
labelled at only one end. Alkylations were performed in sodium
citrate–sodium chloride (SSC) 0.1 ´ buffer at room temperature
for 5 h at doses selected to give approximately one alkylation per
DNA molecule. After precipitation and washing, the DNA was
heated at 90°C for 30 min in 0.1 ´ SSC buffer for N3 alkylation
assay, while for N7 alkylation assay DNA was heated for 15 min at
90°C in 1 M piperidine and then washed twice with water. DNA
fragments were separated on 0.4 mm, 8% polyacrylamide gels
containing 7 M urea and a Tris–boric acid EDTA buffer system.
Gels were run at 55 W (approximately 3000 V) for 3 h, dried and
autoradiographed. DNA sequencing was performed according to
the Maxam and Gilbert assay.
MPE footprinting
The 4492- and 751-bp labelled fragments previously described
were incubated with different concentrations of drugs for 1 h at
room temperature and then treated with a solution of MPE-(NH4)2-
Fe(SO4)2.6H2O (synthetized by Pharmacia & Upjohn according to
published method) (Hertzberg et al, 1984) for 30 min at room
temperature. After precipitation, DNA was resuspended in loading
buffer and electrophoresed on 8% polyacrylamide–7 M urea gels
and autoradiographed.
Taq polymerase stop assay
The procedure employed was an application of a previously
described method (Ponti et al, 1991). Prior to drug-DNA incuba-
tion, plasmid pBSSK-TOPO II was linearized with PstI enzyme
(NEB) to provide a stop for the Taq polymerase downstream from
the primer. After drug treatment, the DNA was precipitated and
washed as described (Ponti et al, 1991). The primers were 5¢-end-
labelled prior to amplification using T4 polynucleotide kinase
(NEB) and g-32P-ATP (5000 Ci mmol–1, Amersham). The synthetic
primer sequence and the polymerase chain reaction (PCR) linear
DNA amplification were performed as described (Ponti et al,
1991; Marchini et al, 1998). Samples were then purified and
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Table 1 Cytotoxicity of PNU 151807 and tallimustine (IC50, ng ml–1)
Cell line PNU 151807 Tallimustine R
L1210 9.64 ± 1.37 84.8 ± 12 8.79
B16F10 29.64 ± 2.4 1096 ± 286 36.97
Jurkat 22.85 ± 2.3 13.8 ± 2.4 0.6
CEM 19.8 ± 3.4 10.2 ± 1.8 0.5
HT29 658.5 ± 77 4177 ± 928 6.3
LoVo 106.4 ± 21 826 ± 155 7.79
A2780 12.54 ± 4.3 378 ± 16 30
DU145 69.19 ± 1.8 55.6 ± 27 0.8
R = Ratio between IC50 of tallimustine and PNU 151807.
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Figure 1 Chemical structure of distamycin A, tallimustine and PNU 151807loaded on 8% polyacrylamide denaturing gel. After the run, the gel
was dried and autoradiographed.
Western blot analysis
Total cell extracts were prepared from untreated or treated cells at
different times after drug exposure, according to standard proce-
dures (Sambrook et al, 1989). 20 mg of proteins for each sample
were electrophoresed through 12% polyacrylamide-sodium
dodecyl sulphate (SDS) gels and electroblotted onto nitrocellulose
membrane (Schleicher & Schull, Germany) in transfer buffer
(50 mM Tris, 100 mM glycine, 0.01% SDS, 20% methanol) for 2 h
at 50 V. Filters were stained with Ponceau red, hybridized with
monoclonal antibody against p53 (clone DO-1), and detected with
the enhanced chemiluminiscence system (ECL). The experiments
were repeated in all the cell lines at least twice.
Northern blot analysis
Total RNA was extracted from untreated or treated cells with the
guanidine/caesium chloride gradient method (Sambrook et al,
1989). After fractionation through 1% agarose-formaldehyde gels,
RNA was blotted on nylon membranes (GeneScreen plus, Dupont)
and hydridized with cDNAs encoding bax (kindly supplied by Dr
Korsmeyer, St Louis, MO, USA) and WAF1. Each cDNA was 32P-
labelled using a Rediprime kit (Amersham, UK). Hybridizations
were performed in 50% formamide, 10% dextran suphate, 1%
SDS, 1 M sodium chloride at 42°C for 16 h, followed by two
washes at room temperature for 10 min with 2 ´ SSC (150 mM
sodium chloride, 15 mM sodium citrate) and one wash for 30 min
at 65°C in 2 ´ SSC–1% SDS. WAF1 cDNA was obtained by PCR
as previously described (Vikhanskaya et al, 1994). Each filter was
hybridized with a-actin cDNA to normalize for RNA loading.
Cyclin-dependent kinase (cdk) activity
Inhibition of kinase activity was measured as previously reported
(Bonfanti et al, 1997) by incubating 100 ng of total extracts
containing insect cell-expressed cyclin E–cdk2, cyclin A–cdk2 or
cyclin B–cdc2 in the presence of different drug concentrations at
4°C for 30 min. Kinase reactions were followed at 30°C for
20 min in a total volume of 25 ml of kinase buffer (50 mM Tris–
HCl pH 7.4, 150 mM sodium chloride, 0.5% Triton X-100, 10 mM
magnesium chloride, 1 mM dithiothreitol) containing 2 mg of
histone H1, 1 mM ATP and 5 mCi [g-32P]ATP (5000 Ci mmol–1;
Amersham); 25 ml of 2 ´ SDS-loading buffer were added and the
samples were boiled and loaded on 12% SDS polyacrylamide gels.
Histone H1 was loaded as a marker of molecular weight and
separately stained with Coomassie blue.
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Figure 2 MPE footprinting analysis in the 751-bp EcoRI–BamH1 fragment
of SV40. G and G+A are Maxam and Gilbert sequencing reaction for
guanines and guanines plus adenines, respectively. Lane 1, distamycin A
(250 mM); lane 2, tallimustine (250 mM); lane 3, PNU 151807 (250 mM).
Protected regions are evidentiated by a mark on the right side. C: control,
untreated DNA
Figure 3 DNA alkylation assay. (A) Sites of N3 adenine alkylation produced
by drugs in EcoRI-digested SV40 DNA, 32P-labelled at the 5¢ end and further
cleaved with BamHI. Lane 1, tallimustine (250 mM); lane 2, tallimustine
(500 mM); lane 3, PNU151807 (500 mM). (B) Taq polymerase stop assay on
pBSSK-TOPO II DNA incubated with different drugs. Lane 1, distamycin
(10 mM); lane 2, tallimustine (10 mM); lane 3, PNU 151807 (10 mM)
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ABRESULTS
The cytotoxic activity of PNU 151807 in comparison with
tallimustine (see structure in Figure 1), evaluated in different cell
lines, is reported in Table 1. With the exception of CEM and Jurkat
cell lines (in which tallimustine seemed to be twice as potent as
PNU 151807) and DU145 (in which the two compounds had
roughly the same cytotoxicity), in all the other cancer cell lines
tested PNU 151807 showed higher cytotoxicity than the parental
alkylating agent tallimustine. Non-covalent DNA interactions of
PNU 151807 and tallimustine were initially evaluated by foot-
printing analysis. Figure 2 reports a representative experiment
conducted in parallel with distamycin A and shows that both
the compounds tested protect quite the same AT-rich region as
distamycin A. Analysis of different DNA fragments and sequences
did not reveal any significant difference in the non-covalent DNA
interaction among the different compounds. Differences in band
intensity may be due to differences in gel loading.
PNU 151807 was then tested for its ability to covalently interact
with DNA. By testing different DNA sequences with the N3-
adenine alkylation assay, we failed to detect any alkylation. Figure
3A reports an example of these gels in which in the same treatment
conditions aklylation by tallimustine was detectable in the target
sequence 5¢-TTTTGA (increasing the drug-DNA incubation times
and the heating treatment to detect breaks at adenine N3 failed to
reveal any alkylation, data not shown). The lack of covalent PNU
151807–DNA interaction was further confirmed by Taq stop assay
which allows the detection also of adducts different from those
produced at N3 adenine (as for example those produced at N2-
guanine). As we can see from Figure 3B, PNU 151807 is unable to
produce any kind of alkylation in the examined sequences. DNA
incubation with PNU 151807 was even prolonged to 24 h and
tested in different DNA sequences, but again we failed to detect
any kind of alkylation (data not shown). Trying to elucidate the
mechanism of action of PNU 151807, the human ovarian cancer
cell line A2780 and a subline derived from it in which wild-type
p53 has been disrupted (A2780/E6) have been selected and tested
for the growth inhibition produced by the two compounds. The
data obtained showed that the two compounds were only slightly
more cytotoxic in cells not expressing p53 being the ratio between
the IC50 in A2780 and A2780/E6 2.7 and 2.1, respectively, for
tallimustine and PNU 151807.
We then evaluated whether treatment of the cells with concen-
trations close to the IC50 was able to activate p53 and subsequently
p21 and bax genes. By Western blotting analysis, we could detect
a clear induction of p53 after treatment with both compounds in
A2780 cells (Figure 4). As expected in A2780/E6 both compounds
did not induce the expression of p53. The increase in the p53
protein levels, observed in A2780 cells, was associated with an
increase in the mRNA levels of two genes transcriptionally regu-
lated by p53, i.e. WAF1 and, to a lesser extent BAX (Figure 5).
The cell cycle perturbation induced by PNU 151807 and
tallimustine was evaluated at different times of incubation in drug-
free medium after 1 h treatment with equitoxic concentrations in
A2780 cells. As reported in Figure 6 both compounds produced an
accumulation of cells in G2, evident after 24 h incubation in drug-
free medium for PNU 151807 and later (48 h after incubation) for
tallimustine.
To further analyse PNU 151807 effects on cell cycle proteins,
we tested whether both PNU 151807 and tallimustine were able to
interfere with the kinase activity of cdk. We incubated different
concentrations of the compounds with baculovirus produced
recombinant CDK2–cyclin A, CDK2–cyclin E and cdc2–cyclin B,
and then evaluated the kinase activity measured as ability to phos-
phorylate in vitro histone H1. As shown in Figure 7, PNU 151807
inhibited CDK2 kinase activity when complexed with cyclin A or
cyclin E. At the same concentrations tested, neither tallimustine
nor distamycin A caused inhibition of the kinase activity, with
only marginal effect observable at the highest concentrations. The
same was observable for cdc2 whose activity was inhibited at
significant extent only by PNU 151807. The experiments were
repeated at least three times for each kinase with essentially the
same results.
DISCUSSION
Minor groove alkylating binders are a new class of anticancer
agents reported to possess high anti-tumour activity in both in
vitro and in vivo experimental models (D’Incalci, 1994). In partic-
ular, a number of distamycin A derivatives have been tested for
their cytotoxic activity and compared with tallimustine, the first
alkylating distamycin derivative entered into phase I clinical trials
(Sessa et al, 1994). The activity of this class of compounds has
been related to their ability to alkylate DNA, in a very high
sequence-specific manner with the N3 of adenine in the minor
groove as main target (Coley et al, 1990; Broggini et al, 1991,
1995). In general, loss of alkylating ability has been associated
with a dramatic loss of cytotoxic activity in vitro (Marchini et al,
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Figure 4 Western blotting analysis of p53 expression in A2780 and
A2780/E6 cells after 1, 6 and 24 h of treatment with the respective IC50 of
tallimustine and PNU 151807. C: controls, untreated cells
C PNU 151807 C TALLIM.
162 4 162 4 Time (h)
WAF1
BAX
Actin
Figure 5 mRNA expression of WAF1 and BAX in A2780 cells after 1, 6 and
24 h of treatment with tallimustine and PNU 151807 at the respective IC50s1998), suggesting that the mechanism of action is related to the
covalent DNA interaction occurring between the alkylating moiety
of the compounds and the N3-adenine of DNA.
The a-bromoacryloyl derivative of distamycin A PNU 151807,
is clearly an exception to these observations, as it has equal or even
superior cytotoxic activity when compared to tallimustine, but
does not appear to covalently interact with DNA as indicated by
the DNA alkylation experiments reported here.
These data fit with the chemical available data which indicate
a poor reactivity of the bromoacryloyl group when linked to the
distamycin moiety. In fact, the molecule was proved to be stable at
room temperature for 3 days at pH 12. Moreover, it was stable when
heated at 60°C for 48 h in acetone:water at pH 10, conditions leading
to hydrolysis of nitrogen mustards, even of those with low reactivity
such as tallimustine (P Cozzi et al, manuscript in preparation). The
lack of covalent interaction was not due to inability of the modified
distamycin backbone to interact with DNA, since the footprinting
experiments revealed that PNU 151807 protected the same DNA
regions protected by tallimustine and distamycin A. Since distamycin
A is devoid of any anti-tumour activity, unless utilizing very high
concentrations (Geroni et al, 1993), the bromoacryloyl part of the
molecule must have a biological relevance for cytotoxicity.
Both tallimustine and PNU 151807 are able to increase the
levels of p53 in A2780 cells, and this increase was associated to an
increased transcriptional activation as judged by the raise in the
mRNA levels of WAF1 gene. Nevertheless, the presence of p53
does not play a significant role in determining the cytotoxicity of
these two compounds in A2780 cells. Utilizing a clone obtained
from A2780 cells and previously reported to have disruption of
p53 function (Vikhanskaya et al, 1998), we only observed a slight
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Figure 6 Cell cycle perturbations induced by PNU 151807 (panels C, E, G) and tallimustine (panels B, D, F) in A2780 cells treated with the respective IC50s for
1 h. Analysis were performed after 24 (panels B, C), 48 (panels D, E) and 72 (panels F, G) h incubation in drug-free medium. Controls, untreated cells are in
panel (A)increase in the activity of both compounds, while in the same
system we have reported that the widely used anticancer agent
taxol showed a markedly increased (roughly 50 times) activity in
A2780/E6 cells compared with the parental cell line (Vikhanskaya
et al, 1998). Nevertheless, the increase in p53 levels induced by
PNU 151807 does not necessarily imply that DNA damage is
occurring as other compounds not directly interacting with DNA
are also able to do it (Tishler et al, 1995).
It has been reported that some compounds with anti-tumour
activity were able to interfere with the phosphorylating activity of
cdk (Drees et al, 1997), and the known cdks are under investiga-
tion as possible targets for the synthesis of new anticancer agents
(Bonfanti et al, 1997).
PNU 151807 is able to inhibit the activity of the complexes
CDK2–cyclin A, CDK2–cyclin E and CDC2–cyclin B when
tested against recombinant proteins in vitro. These findings open
the possibility that the drug action could be through the inhibition
of these important cell cycle controlling proteins. This effect
appears to be independent from the DNA binding activity since
tallimustine or distamycin A only modestly, and at the highest
concentrations tested, interfere with this activity.
In conclusion, PNU 151807 is a new promising anticancer agent
with a mechanism of action different from the previously tested
alkylating minor groove binders (D’Incalci, 1994). Considering
that some of the latter compounds were associated with unex-
pected clinical haematologycal toxicity, and that from studies on
haematologycal precursors maintained in vitro it appears that PNU
151807 had a much lower toxicity and a higher therapeutic
index than tallimustine (Ghielmini et al, 1997), PNU151807 or
analogues of it could represent an interesting clinical alternative to
alkylating minor groove binders.
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